{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:41:09Z","timestamp":1793047269845,"version":"4.5.0"},"update-to":[{"DOI":"10.1371\/journal.pmed.1003566","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000}}],"reference-count":73,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/K012126\/1"],"award-info":[{"award-number":["MR\/K012126\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Global TB Programme of the World Health Organization","award":["ref: 2017\/748478-0"],"award-info":[{"award-number":["ref: 2017\/748478-0"]}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"\nBackground<\/jats:title>\nTwo weeks\u2019 isolation is widely recommended for people commencing treatment for pulmonary tuberculosis (TB). The evidence that this corresponds to clearance of potentially infectious tuberculous mycobacteria in sputum is not well established. This World Health Organization\u2013commissioned review investigated sputum sterilisation dynamics during TB treatment.<\/jats:p>\n<\/jats:sec>\n\nMethods and findings<\/jats:title>\nFor the main analysis, 2 systematic literature searches of OvidSP MEDLINE, Embase, and Global Health, and EBSCO CINAHL Plus were conducted to identify studies with data on TB infectiousness (all studies to search date, 1 December 2017) and all randomised controlled trials (RCTs) for drug-susceptible TB (from 1 January 1990 to search date, 20 February 2018). Included articles reported on patients receiving effective treatment for culture-confirmed drug-susceptible pulmonary TB. The outcome of interest was sputum bacteriological conversion: the proportion of patients having converted by a defined time point or a summary measure of time to conversion, assessed by smear or culture. Any study design with 10 or more particpants was considered. Record sifting and data extraction were performed in duplicate. Random effects meta-analyses were performed. A narrative summary additionally describes the results of a systematic search for data evaluating infectiousness from humans to experimental animals (PubMed, all studies to 27 March 2018). Other evidence on duration of infectiousness\u2014including studies reporting on cough dynamics, human tuberculin skin test conversion, or early bactericidal activity of TB treatments\u2014was outside the scope of this review. The literature search was repeated on 22 November 2020, at the request of the editors, to identify studies published after the previous censor date. Four small studies reporting 3 different outcome measures were identified, which included no data that would alter the findings of the review; they are not included in the meta-analyses. Of 5,290 identified records, 44 were included. Twenty-seven (61%) were RCTs and 17 (39%) were cohort studies. Thirteen studies (30%) reported data from Africa, 12 (27%) from Asia, 6 (14%) from South America, 5 (11%) from North America, and 4 (9%) from Europe. Four studies reported data from multiple continents. Summary estimates suggested smear conversion in 9% of patients at 2 weeks (95% CI 3%\u201324%, 1 single study [N<\/jats:italic> = 1]), and 82% of patients at 2 months of treatment (95% CI 78%\u201386%, N =<\/jats:italic> 10). Among baseline smear-positive patients, solid culture conversion occurred by 2 weeks in 5% (95% CI 0%\u201314%, N<\/jats:italic> = 2), increasing to 88% at 2 months (95% CI 84%\u201392%, N =<\/jats:italic> 20). At equivalent time points, liquid culture conversion was achieved in 3% (95% CI 1%\u201316%, N =<\/jats:italic> 1) and 59% (95% CI 47%\u201370%, N =<\/jats:italic> 8). Significant heterogeneity was observed. Further interrogation of the data to explain this heterogeneity was limited by the lack of disaggregation of results, including by factors such as HIV status, baseline smear status, and the presence or absence of lung cavitation.<\/jats:p>\n<\/jats:sec>\n\nConclusions<\/jats:title>\nThis systematic review found that most patients remained culture positive at 2 weeks of TB treatment, challenging the view that individuals are not infectious after this interval. Culture positivity is, however, only 1 component of infectiousness, with reduced cough frequency and aerosol generation after TB treatment initiation likely to also be important. Studies that integrate our findings with data on cough dynamics could provide a more complete perspective on potential transmission of Mycobacterium tuberculosis<\/jats:italic> by individuals on treatment.<\/jats:p>\n<\/jats:sec>\n\nTrial registration<\/jats:title>\nSystematic review registration:<\/jats:bold> PROSPERO 85226<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1003566","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T19:57:05Z","timestamp":1619467025000},"page":"e1003566","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["Dynamics of sputum conversion during effective tuberculosis treatment: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1926-7464","authenticated-orcid":true,"given":"Claire J.","family":"Calderwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3615-4928","authenticated-orcid":true,"given":"James P.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6524-3754","authenticated-orcid":true,"given":"Katherine L.","family":"Fielding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2636-1520","authenticated-orcid":true,"given":"Rebecca C.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9643-664X","authenticated-orcid":true,"given":"Aaron S.","family":"Karat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9456-5859","authenticated-orcid":true,"given":"Raoul","family":"Mansukhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7329-0577","authenticated-orcid":true,"given":"Jane","family":"Falconer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Bergstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8848-9135","authenticated-orcid":true,"given":"Sarah M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1409-8531","authenticated-orcid":true,"given":"Nicky","family":"McCreesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9546-9650","authenticated-orcid":true,"given":"Edward J. M.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6030-7878","authenticated-orcid":true,"given":"Jasantha","family":"Odayar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5292-6604","authenticated-orcid":true,"given":"Peter J.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Theodorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3748-0154","authenticated-orcid":true,"given":"David A. J.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"key":"pmed.1003566.ref001","volume-title":"Global tuberculosis report 2019","author":"World Health Organization","year":"2019"},{"issue":"5","key":"pmed.1003566.ref002","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1164\/rccm.201203-0444OC","article-title":"Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis","volume":"186","author":"KP Fennelly","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"pmed.1003566.ref003","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1164\/rccm.201208-1422OC","article-title":"Cough aerosols of Mycobacterium tuberculosis predict new infection: a household contact study","volume":"187","author":"EC Jones-L\u00f3pez","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"pmed.1003566.ref004","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/cid\/cix039","article-title":"Dynamics of cough frequency in adults undergoing treatment for pulmonary tuberculosis","volume":"64","author":"A Proa\u00f1o","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pmed.1003566.ref005","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0041-3879(76)80006-2","article-title":"Transmission of tubercle bacilli: the effects of chemotherapy","volume":"57","author":"A Rouillon","year":"1976","journal-title":"Tubercle"},{"key":"pmed.1003566.ref006","volume-title":"NICE guideline [NG33]","author":"National Institute for Health and Care Excellence","year":"2019"},{"issue":"RR\u201317","key":"pmed.1003566.ref007","first-page":"1","article-title":"Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005","volume":"54","author":"Centers for Disease Control and Prevention","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"pmed.1003566.ref008","volume-title":"Canadian tuberculosis standards 7th edition: 2014","author":"Public Health Agency of Canada","year":"2014"},{"key":"pmed.1003566.ref009","volume-title":"National infection prevention and control guidelines for TB, MDR-TB and XDR-TB","author":"Republic of South Africa Department of Health","year":"2015"},{"issue":"4","key":"pmed.1003566.ref010","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1086\/655127","article-title":"Prolonged infectiousness of tuberculosis patients in a directly observed therapy short\u2010course program with standardized therapy","volume":"51","author":"SP Fitzwater","year":"2010","journal-title":"Clin Infect Dis"},{"key":"pmed.1003566.ref011","first-page":"109","article-title":"Cough frequency and infectivity in patients with pulmonary tuberculosis","volume":"99","author":"RG Loudon","year":"1969","journal-title":"Am Rev Respir Dis"},{"key":"pmed.1003566.ref012","volume-title":"WHO guidelines on tuberculosis infection prevention and control, 2019 update","author":"World Health Organization","year":"2019"},{"issue":"7","key":"pmed.1003566.ref013","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS Med"},{"key":"pmed.1003566.ref014","volume-title":"Guidelines for treatment of drug-susceptible tuberculosis and patient care\u20142017 update","author":"World Health Organization","year":"2017"},{"key":"pmed.1003566.ref015","volume-title":"Study quality assessment tools: quality assessment tool for case series studies","author":"National Institutes of Health","year":"2020"},{"key":"pmed.1003566.ref016","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1214\/aoms\/1177729756","article-title":"Transformations related to the angular and the square root","volume":"21","author":"MF Freeman","year":"2007","journal-title":"Ann Math Stat"},{"key":"pmed.1003566.ref017","article-title":"Functions in meta (1.5\u20130)","author":"G. Schwarzer","year":"2010","journal-title":"RDocumentation"},{"issue":"1","key":"pmed.1003566.ref018","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s12879-018-3309-0","article-title":"Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar","volume":"18","author":"MH Al-Shaer","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"12","key":"pmed.1003566.ref019","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S2213-2600(19)30366-2","article-title":"Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial","volume":"7","author":"CD Tweed","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"1","key":"pmed.1003566.ref020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1473-3099(18)30480-8","article-title":"Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial","volume":"19","author":"JK Lee","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"pmed.1003566.ref021","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201712-2524OC","article-title":"Efficacy and safety of high-dose rifampin in pulmonary tuberculosis a randomized controlled trial","volume":"198","author":"GE Vel\u00e1squez","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"pmed.1003566.ref022","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.rmed.2004.08.016","article-title":"Effect of cigarette smoking on sputum smear conversion in adults with active pulmonary tuberculosis","volume":"99","author":"AT Abal","year":"2005","journal-title":"Respir Med"},{"issue":"5","key":"pmed.1003566.ref023","first-page":"407","article-title":"Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis. Groupe de Travail sur la Chimioth\u00e9rapie de la Tuberculose","volume":"76","author":"P Chaulet","year":"1995","journal-title":"Tuber Lung Dis"},{"issue":"9670","key":"pmed.1003566.ref024","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(09)60333-0","article-title":"Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial","volume":"373","author":"MB Conde","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"pmed.1003566.ref025","doi-asserted-by":"crossref","first-page":"e0154778","DOI":"10.1371\/journal.pone.0154778","article-title":"A phase 2 randomized trial of a rifapentine plus moxifloxacin-based regimen for treatment of pulmonary tuberculosis","volume":"11","author":"MB Conde","year":"2016","journal-title":"PLoS ONE"},{"issue":"9","key":"pmed.1003566.ref026","doi-asserted-by":"crossref","first-page":"e6984","DOI":"10.1371\/journal.pone.0006984","article-title":"Immunomodulation with recombinant interferon-\u03b31b in pulmonary tuberculosis","volume":"4","author":"R Dawson","year":"2009","journal-title":"PLoS ONE"},{"issue":"9979","key":"pmed.1003566.ref027","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/S0140-6736(14)62002-X","article-title":"Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul.","volume":"385","author":"R Dawson","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"pmed.1003566.ref028","doi-asserted-by":"crossref","first-page":"780","DOI":"10.5588\/ijtld.14.0868","article-title":"Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis","volume":"19","author":"R Dawson","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"pmed.1003566.ref029","first-page":"203","article-title":"Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy","volume":"160","author":"LE Desjardin","year":"1999","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"6","key":"pmed.1003566.ref030","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.rmed.2005.09.026","article-title":"Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis","volume":"100","author":"D Dlugovitzky","year":"2006","journal-title":"Respir Med"},{"issue":"5","key":"pmed.1003566.ref031","first-page":"432","article-title":"Factors associated with time to sputum smear conversion in active pulmonary tuberculosis","volume":"7","author":"A Dom\u00ednguez-Castellano","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"pmed.1003566.ref032","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1164\/rccm.200901-0078OC","article-title":"Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis","volume":"180","author":"SE Dorman","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"pmed.1003566.ref033","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/infdis\/jis461","article-title":"Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: Study 29 of the tuberculosis trials consortium","volume":"206","author":"SE Dorman","year":"2012","journal-title":"J Infect Dis"},{"issue":"3","key":"pmed.1003566.ref034","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1164\/rccm.201410-1843OC","article-title":"Daily rifapentine for treatment of pulmonary tuberculosis: A randomized, dose-ranging trial","volume":"191","author":"SE Dorman","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"pmed.1003566.ref035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0041-3879(83)90011-9","article-title":"Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis","volume":"64","author":"East and Central African\/British Medical Research Council","year":"1983","journal-title":"Tubercle"},{"issue":"6","key":"pmed.1003566.ref036","doi-asserted-by":"crossref","first-page":"e1001843","DOI":"10.1371\/journal.pmed.1001843","article-title":"Transmission of multidrug-resistant and drug-susceptible tuberculosis within households: a prospective cohort study","volume":"12","author":"L Grandjean","year":"2015","journal-title":"PLoS Med"},{"key":"pmed.1003566.ref037","first-page":"171","article-title":"Controlled trial of four thrice-weekly regimens and a daily regimen all given for six months for pulmonary tuberculosis","volume":"317","author":"Hong Kong Chest Service\/British Medical Research Council","year":"1981","journal-title":"Lancet"},{"key":"pmed.1003566.ref038","first-page":"219","article-title":"Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis.","volume":"118","author":"Hong Kong Chest Service\/British Medical Research Council","year":"1978","journal-title":"Am Rev Respir Dis"},{"issue":"17","key":"pmed.1003566.ref039","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-dose rifapentine with moxifloxacin for pulmonary tuberculosis","volume":"371","author":"A Jindani","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"pmed.1003566.ref040","doi-asserted-by":"crossref","first-page":"832","DOI":"10.5588\/ijtld.15.0577","article-title":"A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis","volume":"20","author":"A Jindani","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"pmed.1003566.ref041","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1086\/315393","article-title":"Randomized controlled trial of Mycobacterium vaccae immunotherapy in non\u2013human immunodeficiency virus\u2013infected Ugandan adults with newly diagnosed pulmonary tuberculosis","volume":"181","author":"JL Johnson","year":"2000","journal-title":"J Infect Dis"},{"issue":"2","key":"pmed.1003566.ref042","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1164\/rccm.200211-1359OC","article-title":"Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis","volume":"168","author":"JL Johnson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"pmed.1003566.ref043","first-page":"528","article-title":"Quantitative sputum bacillary load during rifampin-containing short course chemotherapy in human immunodeficiency virus-infected and non-infected adults with pulmonary tuberculosis","volume":"4","author":"ML Joloba","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"pmed.1003566.ref044","doi-asserted-by":"crossref","first-page":"e0142607","DOI":"10.1371\/journal.pone.0142607","article-title":"Factors affecting time to sputum culture conversion in adults with pulmonary tuberculosis: a historical cohort study without censored cases","volume":"10","author":"R Kanda","year":"2015","journal-title":"PLoS ONE"},{"issue":"5","key":"pmed.1003566.ref045","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/clinids\/22.5.827","article-title":"Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis","volume":"22","author":"N Kennedy","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"11","key":"pmed.1003566.ref046","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1086\/502145","article-title":"Relative versus absolute noncontagiousness of respiratory tuberculosis on treatment","volume":"24","author":"R Long","year":"2003","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"6","key":"pmed.1003566.ref047","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.medmal.2016.04.010","article-title":"Active pulmonary tuberculosis: role for amikacin in early treatment","volume":"46","author":"F M\u00e9cha\u00ef","year":"2016","journal-title":"Med Mal Infect"},{"issue":"7","key":"pmed.1003566.ref048","first-page":"792","article-title":"Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting","volume":"12","author":"C Pheiffer","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"pmed.1003566.ref049","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.5588\/ijtld.12.0122","article-title":"Risk and outcome of multidrug-resistant tuberculosis: Vitamin D receptor polymorphisms and serum 25(OH)D","volume":"16","author":"J Rathored","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"pmed.1003566.ref050","first-page":"579","article-title":"Clinical trial of 6-month and 4-month regimens of chemotherapy in the treatment of pulmonary tuberculosis","volume":"119","author":"Singapore Tuberculosis Service\/British Medical Research Council","year":"1979","journal-title":"Am Rev Respir Dis"},{"issue":"2","key":"pmed.1003566.ref051","first-page":"374","article-title":"Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis","volume":"132","author":"Singapore Tuberculosis Service\/British Medical Research Council","year":"1985","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"pmed.1003566.ref052","first-page":"58","article-title":"Factors predicting persistent sputum smear positivity among pulmonary tuberculosis patients 2 months after treatment","volume":"7","author":"R Singla","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"pmed.1003566.ref053","first-page":"9","article-title":"Treatment of pulmonary tuberculosis in a low-prevalence urban area. Compliance and sputum conversion","volume":"74","author":"C Stoffel","year":"2014","journal-title":"Medicina (B Aires)"},{"issue":"5","key":"pmed.1003566.ref054","first-page":"727","article-title":"Controlled clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis","volume":"131","author":"Tanzania\/British Medical Research Council","year":"1985","journal-title":"Am Rev Respir Dis"},{"issue":"8","key":"pmed.1003566.ref055","first-page":"960","article-title":"A controlled trial of a 4-weekly supplement of rifampicin, pyrazinamide and streptomycin in the continuation phase of a 7-month daily chemotherapy regimen for pulmonary tuberculosis","volume":"86","author":"Tanzania\/British Medical Research Council","year":"1996","journal-title":"South African Med J"},{"issue":"3","key":"pmed.1003566.ref056","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1086\/513772","article-title":"Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis","volume":"25","author":"EE Telzak","year":"1997","journal-title":"Clin Infect Dis"},{"key":"pmed.1003566.ref057","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0007-0971(81)90046-2","article-title":"A controlled trial of six months chemotherapy in pulmonary tuberculosis. First report: results during chemotherapy","volume":"75","author":"British Thoracic Association","year":"1981","journal-title":"Br J Dis Chest"},{"issue":"6","key":"pmed.1003566.ref058","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7326\/0003-4819-76-3-112-6-397","article-title":"USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. The report of final results","volume":"112","author":"DL Combs","year":"1990","journal-title":"Ann Intern Med"},{"issue":"8","key":"pmed.1003566.ref059","doi-asserted-by":"crossref","first-page":"e103768","DOI":"10.1371\/journal.pone.0103768","article-title":"Culture conversion rate at 2 months of treatment according to diagnostic methods among patients with culture-positive pulmonary tuberculosis","volume":"9","author":"HY Lee","year":"2014","journal-title":"PLoS ONE"},{"issue":"6","key":"pmed.1003566.ref060","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/resp.13017","article-title":"Effects of diabetes mellitus on the clinical presentation and treatment response in tuberculosis","volume":"22","author":"CC Leung","year":"2017","journal-title":"Respirology"},{"issue":"6","key":"pmed.1003566.ref061","first-page":"386","article-title":"Factors associated with sputum culture conversion in patients with pulmonary tuberculosis","volume":"53","author":"G Musteikien\u0117","year":"2017","journal-title":"Med"},{"issue":"3","key":"pmed.1003566.ref062","first-page":"450","article-title":"Addition of amikacin and levofloxacin is associated with higher culture conversion rate in pulmonary tuberculosis","volume":"5","author":"MUD Sajid","year":"2011","journal-title":"Pakistan J Med Heal Sci"},{"issue":"3","key":"pmed.1003566.ref063","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3201\/eid2303.161916","article-title":"Comparison of sputum-culture conversion for Mycobacterium bovis and M. tuberculosis","volume":"23","author":"C Scott","year":"2017","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"pmed.1003566.ref064","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0041-3879(83)90032-6","article-title":"Study of chemotherapy regimens of 5 and 7 months\u2019 duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India","volume":"64","author":"Tuberculosis Research Centre","year":"1983","journal-title":"Tubercle"},{"issue":"1","key":"pmed.1003566.ref065","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5588\/ijtld.14.0516","article-title":"Tuberculosis and excess alcohol use in the United States, 1997\u20132012","volume":"19","author":"T Volkmann","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"issue":"7","key":"pmed.1003566.ref066","doi-asserted-by":"crossref","first-page":"878","DOI":"10.5588\/ijtld.12.0732","article-title":"Association between Mycobacterium tuberculosis lineage and time to sputum culture conversion","volume":"17","author":"ES Click","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"pmed.1003566.ref067","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1513\/AnnalsATS.201702-147OC","article-title":"Isoniazid monoresistance and rate of culture conversion among patients in the state of Georgia with confirmed tuberculosis, 2009\u20132014","volume":"15","author":"AD Salindri","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"pmed.1003566.ref068","first-page":"511","article-title":"Infectiousness of air from a tuberculosis ward. Ultraviolet irradiation of infected air: comparative infectiousness of different patients","volume":"85","author":"RL Riley","year":"1962","journal-title":"Am Rev Respir Dis"},{"issue":"10","key":"pmed.1003566.ref069","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1086\/515397","article-title":"The detection of airborne transmission of tuberculosis from HIV-infected patients, using an in vivo air sampling model","volume":"44","author":"AR Escombe","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"9","key":"pmed.1003566.ref070","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1371\/journal.pmed.0050188","article-title":"The infectiousness of tuberculosis patients coinfected with HIV","volume":"5","author":"AR Escombe","year":"2008","journal-title":"PLoS Med"},{"issue":"9","key":"pmed.1003566.ref071","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.5588\/ijtld.13.0834","article-title":"Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis","volume":"18","author":"AS Dharmadhikari","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"pmed.1003566.ref072","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3389\/fmicb.2015.01184","article-title":"Rapid culture-based diagnosis of pulmonary tuberculosis in developed and developing countries","volume":"6","author":"S Asmar","year":"2015","journal-title":"Front Microbiol"},{"issue":"9","key":"pmed.1003566.ref073","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S1473-3099(06)70578-3","article-title":"Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review","volume":"6","author":"KR Steingart","year":"2006","journal-title":"Lancet Infect Dis"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1003566","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T19:20:10Z","timestamp":1620674410000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":73,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003566","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pmed.1003566","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]}}}